Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo

International Journal of Cancer

Volumn 131, Issue 1, 2012, Pages 18-29

  Alcazar, Oscar ^a   Achberger, Susan ^a   Aldrich, Wayne ^a   Hu, Zhenbo ^a   Negrotto, Soledad ^a   Saunthararajah, Yogen ^a   Triozzi, Pierre ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

decitabine; differentiation; DNA methyl transferase 1; DNMT1; melanoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 1; PROTEIN P53; TRANSCRIPTION FACTOR SOX9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; EPIGENETICS; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BASE SEQUENCE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE ANALYSIS, DNA; SOX9 TRANSCRIPTION FACTOR; TETRAHYDROURIDINE; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84856377986     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26320     Document Type: Article

References (50)

1. Bellet RE, Catalano RB, Mastrangelo MJ, Berd D,. Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma. Med Pediatr Oncol 1978; 4: 11-5.
2. Creagan ET, Schaid DJ, Hartmann LC, Loprinzi CL,. A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma. Am J Clin Oncol 1993; 16: 243-4.
3. Dahl C, Guldberg P,. The genome and epigenome of malignant melanoma. APMIS 2007; 115: 1161-76.
4. Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM,. The EORTC early clinical trials cooperative group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 1987; 23: 1921-4.
5. Aparicio A, Eads CA, Leong LA, Laird PW, Newman EM, Synold TW, Baker SD, Zhao M, Weber JS,. Phase I trial of continuous infusion 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol 2003; 51: 231-9.
6. Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, Dressman HK, Jelinek J, Issa JP,. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006; 12: 4619-27.
7. Kozar K, Kaminski R, Switaj T, Oldak T, Machaj E, Wysocki PJ, Mackiewicz A, Lasek W, Jakobisiak M, Golab J,. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res 2003; 9: 3124-33.
8. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC,. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 2006; 24: 3771-9.
9. Inomata K, Aoto T, Binh NT, Okamoto N, Tanimura S, Wakayama T, Iseki S, Hara E, Masunaga T, Shimizu H, Nishimura EK,. Genotoxic stress abrogates renewal of melanocyte stem cells by triggering their differentiation. Cell 2009; 137: 1088-99.
10. Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D, Rini B, Saunthararajah Y,. Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res 2011; 71: 1431-41.
11. Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, Gu X, Advani A, Kalaycio M, Sobecks R, Sekeres MA, Copelan E, et al. p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia Leukemia 2011 Jun 24, doi:10.1038/leu.2011.159.
12. Triozzi PL, Walker MJ, Pellegrini AE, Dayton MA,. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest 1996; 14: 293-8.
13. Steigerwald SD, Pfeifer GP,. Variable DNA methylation changes during differentiation of human melanoma cells. Exp Cell Res 1988; 178: 41-50.
14. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA,. Main roads to melanoma. J Transl Med 2009; 7: 86.
15. Passeron T, Valencia JC, Namiki T, Vieira WD, Passeron H, Miyamura Y, Hearing VJ,. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J Clin Invest 2009; 119: 954-63.
16. Sestakova B, Ondrusova L, Vachtenheim J,. Cell cycle inhibitor p21/ WAF1/ CIP1 as a cofactor of MITF expression in melanoma cells. Pigment Cell Melanoma Res 2010; 23: 238-51.
17. Haddad MM, Xu W, Schwahn DJ, Liao F, Medrano EE,. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes. Exp Cell Res 1999; 253: 561-72.
18. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan KK,. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 2006; 20: 1117-26.
19. Qin T, Jelinek J, Si J, Shu J, Issa JP,. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood 2009; 113: 659-67.
20. Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y, Hoffman R,. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood 2004; 103: 4102-10.
21. Hu Z, Negrotto S, Gu X, Mahfouz R, Ng KP, Ebrahem Q, Copelan E, Singh H, Maciejewski JP, Saunthararajah Y,. Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther 2010; 9: 1536-43.
22. Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J,. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003; 102: 3865-70.
23. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D, Wang Y,. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11: 7234-42.
24. Rao P, Fuller GN, Prieto VG,. Expression of Sox-9 in metastatic melanoma-a potential diagnostic pitfall. Am J Dermatopathol 2010; 32: 262-6.
25. Latres E, Malumbres M, Sotillo R, Martin J, Ortega S, Martin-Caballero J, Flores JM, Cordon-Cardo C, Barbacid M,. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 2000; 19: 3496-506.
26. Cooper CD, Raible DW,. Mechanisms for reaching the differentiated state: insights from neural crest-derived melanocytes. Semin Cell Dev Biol 2009; 20: 105-10.
27. Sherbet GV,. Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy. Cancer Lett 2009; 280: 15-30.
28. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M, Ariyan S, Narayan D, Bacchiocchi A, Molinaro A, Kluger Y, Deng M, et al. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS ONE 2009; 4: e4563.
29. Neil GL, Moxley TE, Kuentzel SL, Manak RC, Hanka LJ,. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice. Cancer Chemother Rep 1975; 59: 459-65.
30. Gollob JA, Sciambi CJ,. Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells. Clin Cancer Res 2007; 13: 5219-25.
31. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC,. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene 2008; 27: 490-8.
32. Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, Fox EJ, Culhane AC, McArdle L, Fraga MF, Hughes L, Currid CA, O'Mahony F, et al. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 2005; 26: 1856-67.
33. van der Velden PA, Zuidervaart W, Hurks MH, Pavey S, Ksander BR, Krijgsman E, Frants RR, Tensen CP, Willemze R, Jager MJ, Gruis NA,. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int J Cancer 2003; 106: 472-9.
34. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, Bosenberg M,. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 2006; 66: 11187-93.
35. Jones PA, Taylor SM,. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 85-93.
36. Cruz-Munoz W, Man S, Kerbel RS,. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin Cancer Res 2009; 15: 4867-74.
37. Kitano H,. Cancer robustness: tumour tactics. Nature 2003; 426: 125.
38. Marsh JH, Kreis W, Barile B, Akerman S, Schulman P, Allen SL, DeMarco LC, Schuster MW, Budman DR,. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. Cancer Chemother Pharmacol 1993; 31: 481-4.
39. Cook AL, Smith AG, Smit DJ, Leonard JH, Sturm RA,. Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. Exp Cell Res 2005; 308: 222-35.
40. Chellappan SP, Giordano A, Fisher PB,. Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development. Curr Top Microbiol Immunol 1998; 227: 57-103.
41. Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R,. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 1998; 153: 305-12.
42. El Naaman C, Grum-Schwensen B, Mansouri A, Grigorian M, Santoni-Rugiu E, Hansen T, Kriajevska M, Schafer BW, Heizmann CW, Lukanidin E, Ambartsumian N,. Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene. Oncogene 2004; 23: 3670-80.
43. Nishiyama H, Knopfel T, Endo S, Itohara S,. Glial protein S100B modulates long-term neuronal synaptic plasticity. Proc Natl Acad Sci USA 2002; 99: 4037-42.
44. Hsu MY, Meier F, Herlyn M,. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 2002; 70: 522-36.
45. Nitzki F, Zibat A, Konig S, Wijgerde M, Rosenberger A, Brembeck FH, Carstens PO, Frommhold A, Uhmann A, Klingler S, Reifenberger J, Pukrop T, et al. Tumor stroma-derived Wnt5a induces differentiation of basal cell carcinoma of Ptch-mutant mice via CaMKII. Cancer Res 2010; 70: 2739-48.
46. Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA,. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 2005; 11: 8606-14.
47. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002; 99: 2995-3000.
48. Mishra N, Brown DR, Olorenshaw IM, Kammer GM,. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci USA 2001; 98: 2628-33.
49. Kholmanskikh O, van Baren N, Brasseur F, Ottaviani S, Vanacker J, Arts N, van der BP, Coulie P, De Plaen E,. Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens. Int J Cancer. 2010; 127: 1625-36.
50. Martinez-Esparza M, Jimenez-Cervantes C, Solano F, Lozano JA, Garcia-Borron JC,. Mechanisms of melanogenesis inhibition by tumor necrosis factor-alpha in B16/F10 mouse melanoma cells. Eur J Biochem 1998; 255: 139-46.